Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics Inc (NQ: KRTX )

233.65 +4.39 (+1.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Karuna Therapeutics Inc

< Previous 1 2 Next >
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Karuna
Via Business Wire
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
From PsychoGenics Inc.
Via Business Wire
Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress
From Karuna Therapeutics, Inc.
Via Business Wire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics (NASDAQ: KRTX) Reports Positive Primary and Secondary Endpoint Results from Phase 3 EMERGENT-2 Clinical Trial of KarXT for Treating Schizophrenia
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is engaged as a clinical-stage biopharmaceutical company that is focused on the research and development 
Via Spotlight Growth
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.